
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical is a medical device company with a unique and innovative LIBERTY Endovascular Robotic Surgical System that is expected to experience high growth in the coming years. The company has a strong financial position with significant cash reserves and no debt, providing a solid foundation for commercializing its product. While there is some manufacturing concentration risk through its contract partners in Israel, this is mitigated by the company's plans to expand into additional manufacturing facilities. The recent system-level approvals at major hospitals demonstrate the effectiveness of the product and its potential for wide adoption, and any potential reimbursement risks can be managed through the existing reimbursement codes.
Bears say
Microbot Medical is experiencing slow adoption of its LIBERTY Endovascular Robotic Surgical System, with only 10-11 accounts and 15 hospitals currently using the system, resulting in a lower than expected revenue of $241K in 2Q26. Additionally, the company's expansion into coronary and neurovascular applications will require additional regulatory submissions and associated clinical data requirements, adding to uncertainty and potential delays. The recent limited market release and full market release at the SIR annual scientific meeting show promising adoption and potential for growth, but the addressable market of 2.5M peripheral endovascular procedures in the U.S may be limited. The stock remains a risky investment due to slow adoption, regulatory uncertainties, and limited market potential, therefore a negative outlook is warranted.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares